Universal Vision Biotechnology Co., Ltd.

TPEX:3218 Stock Report

Market Cap: NT$18.0b

Universal Vision Biotechnology Valuation

Is 3218 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 3218 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 3218 (NT$215.5) is trading below our estimate of fair value (NT$435.44)

Significantly Below Fair Value: 3218 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3218?

Key metric: As 3218 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 3218. This is calculated by dividing 3218's market cap by their current earnings.
What is 3218's PE Ratio?
PE Ratio16.8x
EarningsNT$1.08b
Market CapNT$18.00b

Price to Earnings Ratio vs Peers

How does 3218's PE Ratio compare to its peers?

The above table shows the PE ratio for 3218 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average43.8x
1784 BIONET
84.3xn/aNT$4.7b
8403 ShareHope Medicine
24xn/aNT$3.8b
6637 Medical Imaging
17.8xn/aNT$2.5b
6879 TCI GENE
49.3xn/aNT$1.3b
3218 Universal Vision Biotechnology
16.9x10.0%NT$18.3b

Price-To-Earnings vs Peers: 3218 is good value based on its Price-To-Earnings Ratio (16.9x) compared to the peer average (43.8x).

Price to Earnings Ratio vs Industry

How does 3218's PE Ratio compare vs other companies in the Asian Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
3218 16.8xIndustry Avg. 21.2xNo. of Companies48PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 3218 is good value based on its Price-To-Earnings Ratio (16.9x) compared to the Asian Healthcare industry average (21.2x).

Price to Earnings Ratio vs Fair Ratio

What is 3218's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3218 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.8x
Fair PE Ratio15.5x

Price-To-Earnings vs Fair Ratio: 3218 is expensive based on its Price-To-Earnings Ratio (16.9x) compared to the estimated Fair Price-To-Earnings Ratio (15.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 3218 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNT$215.50
NT$215.00
-0.2%
7.0%NT$230.00NT$200.00n/a2
Nov ’25NT$220.00
NT$260.00
+18.2%
11.0%NT$295.00NT$225.00n/a3
Oct ’25NT$256.00
NT$260.00
+1.6%
11.0%NT$295.00NT$225.00n/a3
Sep ’25NT$231.00
NT$271.67
+17.6%
6.1%NT$295.00NT$260.00n/a3
Aug ’25NT$231.50
NT$290.00
+25.3%
1.4%NT$295.00NT$285.00n/a3
Jul ’25NT$251.00
NT$305.00
+21.5%
8.6%NT$350.00NT$285.00n/a4
Jun ’25NT$247.50
NT$305.00
+23.2%
8.6%NT$350.00NT$285.00n/a4
May ’25NT$256.00
NT$313.75
+22.6%
6.9%NT$350.00NT$295.00n/a4
Apr ’25NT$276.50
NT$320.00
+15.7%
6.8%NT$350.00NT$300.00n/a3
Mar ’25NT$304.00
NT$367.50
+20.9%
4.7%NT$392.00NT$350.00n/a4
Feb ’25NT$272.50
NT$372.50
+36.7%
4.0%NT$392.00NT$350.00n/a4
Jan ’25NT$277.00
NT$380.00
+37.2%
5.3%NT$403.00NT$350.00n/a4
Dec ’24NT$291.00
NT$380.00
+30.6%
5.3%NT$403.00NT$350.00n/a4
Nov ’24NT$300.00
NT$422.71
+40.9%
8.8%NT$485.85NT$392.00NT$220.004
Oct ’24NT$336.00
NT$430.45
+28.1%
8.2%NT$485.85NT$392.00NT$256.004
Sep ’24NT$349.00
NT$430.45
+23.3%
8.2%NT$485.85NT$392.00NT$231.004
Aug ’24NT$368.87
NT$419.81
+13.8%
4.8%NT$443.40NT$391.51NT$231.504
Jul ’24NT$400.00
NT$419.81
+5.0%
4.8%NT$443.40NT$391.51NT$251.004
Jun ’24NT$375.47
NT$419.81
+11.8%
4.8%NT$443.40NT$391.51NT$247.504
May ’24NT$378.30
NT$412.97
+9.2%
5.2%NT$434.91NT$391.51NT$256.004
Apr ’24NT$373.11
NT$375.47
+0.6%
13.2%NT$433.96NT$297.17NT$276.504
Mar ’24NT$305.66
NT$343.16
+12.3%
10.3%NT$396.23NT$297.17NT$304.004
Feb ’24NT$312.26
NT$343.16
+9.9%
10.3%NT$396.23NT$297.17NT$272.504
Jan ’24NT$281.60
NT$346.70
+23.1%
10.2%NT$396.23NT$297.17NT$277.004
Dec ’23NT$256.60
NT$346.70
+35.1%
10.2%NT$396.23NT$297.17NT$291.004
Nov ’23NT$236.32
NT$353.74
+49.7%
7.6%NT$396.23NT$323.45NT$300.004

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Concord Medical

NT$866.7m

Provides hospital management support services in Taiwan, Myanmar, and China.

6518

NT$25.85

7D

-3.7%

1Y

9.5%

Pacific Hospital Supply

NT$6.4b

Manufactures, processes, and sells medical disposable products and equipment in Taiwan.

4126

NT$88.60

7D

-0.3%

1Y

5.2%

Hi-Clearance

NT$6.2b

Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.

1788

NT$139.00

7D

0.4%

1Y

3.0%